Clinical Trial Update: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating human plasma-derived C1-esterase inhibitor as add-on therapy to standard of care for refractory antibody-mediated rejection in adult …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Renal Transplant Rejection

Drugs mentioned

• C1-esterase inhibitor

Snippet

Sponsor: CSL Behring | Conditions: Antibody-mediated Rejection | Phase 3 | Status: TERMINATED | Results posted: 2022-01-18